Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6281989 | 0.83 | NPC1 (0.47) | NPC1RAB9AKMT2AHSPA5ALDH1A1 | |
| SCHEMBL7196095 | 0.81 | NPC1 (0.46) | NPC1RAB9AKMT2AHSPA5ALDH1A1 | |
| SCHEMBL6666888 | 0.79 | NPC1 (0.49) | NPC1RAB9AKMT2AHSPA5ALDH1A1 | |
| SCHEMBL50972 | 0.78 | NPC1 (0.43) | NPC1RAB9AKMT2AHSPA5ALDH1A1 | |
| SCHEMBL28882574 | 0.78 | NPC1 (0.47) | NPC1RAB9AKMT2AHSPA5ALDH1A1 | |
| SCHEMBL28612372 | 0.76 | NPC1 (0.46) | NPC1RAB9AKMT2AHSPA5ALDH1A1 | |
| SCHEMBL11599997 | 0.76 | NPC1 (0.46) | NPC1RAB9AKMT2AHSPA5ALDH1A1 | |
| SCHEMBL5829402 | 0.76 | NPC1 (0.48) | NPC1RAB9AKMT2AHSPA5ALDH1A1 | |
| SCHEMBL2004766 | 0.75 | NPC1 (0.52) | NPC1RAB9AKMT2AHSPA5ALDH1A1 | |
| SCHEMBL1324 | 0.75 | NPC1 (0.62) | NPC1RAB9AKMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
| EP-0772597-B1 | 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2001-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | NPC1 3141/4885RAB9A 2869/4885KMT2A 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.